HEMARINA
Franck Zal is the CEO and CSO of HEMARINA, a biotechnology company specializing in the development of oxygen carriers derived from marine worms for therapeutic applications related to ischemia and anemia, as well as industrial uses in bioproduction and stem cell research since March 2007. Prior to this role, Franck Zal worked as a group leader in Ecophysiology at CNRS UMR 7144 from October 1999 to March 2009, where responsibilities included leading research on adaptation and molecular evolution. Educational qualifications include an Executive MBA from Rennes School of Business, an Habilitation à Diriger des Recherches from Pierre and Marie Curie University, and multiple post-doctoral and doctoral degrees focused on biochemistry and marine ecophysiology from renowned universities.
This person is not in any teams
HEMARINA
Hemarina SA. is a privately held biotechnology company focused on the research, and development of oxygen-carriers for medical applications.Dr. Franck Zal, an expert in the field of invertebrate hemoglobin and oxygen transport, founded Hemarina after having spent more than fourteen years in academic research centers (CNRS, University ofCalifornia at Santa Barbara USA and University of Antwerpen, Belgium) studying the relationships between the structure and function of invertebrate respiratory pigment (annelid’s extracellular hemoglobin and crustacean hemocyanin). The discoveries arising from his research on extracellular hemoglobin coming from marine invertebrates and their effective oxygen transport system have been patented and published in numerous scientific journals and form the basis of Hemarina’s technologies.Hemarina’s approach to the development of oxygen transport agents is based on the observation of marine worms colonizing extreme environments and the study of their respiratory adaptations.Hemarina’s lead product, HbAm, is designed to deliver oxygen effectively and efficiently to tissues at risk of oxygen deprivation. Hemarina has already a passed panel of strong proof of concepts obtained during preclinical trials.